Principal Investigators

    Tremblay, Jacques P


    Université Laval

    Contact information of lead PI



    Title of project or programme

    Alzheimer treatment based on the editing of the Amyloid Precursor Protein gene

    Source of funding information


    Total sum awarded (Euro)

    € 103,955

    Start date of award


    Total duration of award in years



    Research Abstract

    Alzheimer disease is due to an accumulation of beta-Amyloïd plaques in the brain. These plaques are produced by the abnormal degradation of the Amyloïd Precursor Protein (APP). This protein in normally cut by the alpha-Secretase enzyme. However, its abnormal digestion by the beta-Secretase leads to the formation of an abnormal protein fragment, which aggregates and accumulates as plaques in the brain. Many mutations of the APP gene favor the formation of these plaques by favorizing the cutting of APP by the beta-Secretase. However, Jonnson et al. (Nature, 2012) have identified in a population of elderly healthy persons a modification of the APP gene, which reduces the digestion of the APP protein by the beta-Secretase and thus prevents Alzheimer. We have recently been able to produce in human cells this specific modification of the APP gene by homologous recombination with a fragment of the APP gene containing this modification. To induce this recombination, the APP gene was cut with a short sequence of RNA (called a gRNA) using the recently developed CRISPR technology. We have also inserted a sequence in the APP gene a sequence of nucleotides, which produce a modification of the APP protein, which was detected with an antibody. I have deposited a patent on this therapeutic approach. The present project aims to improve the specificity and the frequency of the homologous recombination by using simultaneously several pairs of gRNA and a nuclease (the enzyme that cuts the DNA). The project also aims to demonstrate that the production of beta-Amyloid peptide is reduced in 293 T cells and in neurons containing this favorable mutation compared to cells that contain a mutation causing Alzheimer, which favors the formation of Amyloid peptides. We will also produce an Adeno Associated Virus containing all the necessary components to mutate the APP gene in the brain of mouse models of Alzheimer that contains a humanized sequence of the APP gene.

    Further information available at:

Types: Investments < €500k
Member States: Canada
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF